MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
About ZEPATIER
ZEPATIER®▼ (elbasvir and grazoprevir) /
Products /
Root /

About ZEPATIER®▼ (elbasvir and grazoprevir)

Prescribing Information

SIMPLE* POWER TO CURE** FOR CHRONIC HEPATITIS C1-9

Simple, power to cure banner

ZEPATIER is indicated for the treatment of chronic hepatitis C genotypes 1 and 4 infection in adults1

ZEPATIER 12 weeks achieved 95% SVR for treatment naïve patients’ image
ZEPATIER has the power to cure** in People Who Inject Drugs2
Find out more
ZEPATIER for all stages of Chronic Kidney Disease (CKD)3
Find out more
Drug-Drug Interactions and dosing simplicity of ZEPATIER*
Find out more

*'simple' is supported by the information held on the DDIs and dosing simplicity page

**Cure of HCV infection = sustained virologic response (SVR), the primary endpoint in all studies, was defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (LLOQ) (=15 IU/ml) at 12 weeks after the cessation of treatment.1

**Cure of HCV infection = sustained virologic response (SVR), the primary endpoint in all studies, was defined as hepatitis C virus (HCV) ribonucleic acid (RNA) less than the lower limit of quantification (LLOQ)
(=15 IU/ml) at 12 weeks after the cessation of treatment.1

Related content

Default Image
Rating

About ISENTRESS® 600 mg (raltegravir)

Prescribing Information

 

References

  1. ZEPATIER summary of Product Characteristics.
  2. Dore GL et al, Ann Int Med 2016;doi:10.7326/M16-0816 [Epub ahead of print]
  3. Roth D et al. Lancet 2015:386:1537-1545.
  4. Rockstroh JK et al. Lancet HIV 2015:2(8);319-327.
  5. Zeuzem S et al. Ann Intern Med 2015; 163:1-13.
  6. Forns X et al. J Hepatol 2015;63:564-572.
  7. Kwo PY et al. C-EDGE TE EASL 2015.
  8. Sperl J et al. Presented at EASL April 13-17 2016; Barcelona Spain: Abstract PS002.
  9. Jacobson IM et al. Presented at: 66th Annual Meeting of the American Association for the Study of Liver Diseases; November 13-17 2015; Boston, MA.
  10. Europena Association for the Study of the Liver. J Hepatol 2015;63:199-236.

GB-ZEP-00141 | Date of Preparation: May 2021